Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review

Bimekizumab is the most recent interleukin-17 inhibitor (IL-17i) to receive approval for adult plaque psoriasis; unlike other IL-17i agents, it exclusively targets IL-17A/IL-17F. While biologic switching is common in routine clinical practice, limited information exists on switching from another IL-17i agent to bimekizumab. We conducted a real-world, multicenter, retrospective study of bimekizumab use in the setting of prior IL-17i exposure.比美吉珠单抗（bimekizumab）是目前获批用于成人斑块状银屑病的最新白细胞介素-17抑制剂（interleukin-17 inhibitor, IL-17i）；与其他IL-17i类药物不同，它仅靶向IL-17A与IL-17F。尽管生物制剂换药在日常临床实践中十分常见，但现有关于从其他IL-17i类药物换用比美吉珠单抗的研究资料仍较为匮乏。本研究针对既往暴露于IL-17抑制剂的患者，开展了一项关于比美吉珠单抗使用情况的真实世界多中心回顾性研究。